Logo image of MNKD

MANNKIND CORP (MNKD) Stock Fundamental Analysis

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

5.76  +0.1 (+1.77%)

After market: 5.8001 +0.04 (+0.7%)

Fundamental Rating

5

Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 571 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year MNKD was profitable.
MNKD had a positive operating cash flow in the past year.
In the past 5 years MNKD always reported negative net income.
In the past 5 years MNKD reported 4 times negative operating cash flow.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M -300M

1.2 Ratios

MNKD's Return On Assets of 4.65% is amongst the best of the industry. MNKD outperforms 94.85% of its industry peers.
MNKD has a better Return On Invested Capital (11.54%) than 96.09% of its industry peers.
Industry RankSector Rank
ROA 4.65%
ROE N/A
ROIC 11.54%
ROA(3y)-19.1%
ROA(5y)-33.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

MNKD has a better Profit Margin (8.07%) than 94.85% of its industry peers.
MNKD's Operating Margin of 21.43% is amongst the best of the industry. MNKD outperforms 96.27% of its industry peers.
MNKD has a better Gross Margin (71.91%) than 83.66% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.43%
PM (TTM) 8.07%
GM 71.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.96%
GM growth 5Y21.68%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MNKD is still creating some value.
MNKD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
The debt/assets ratio for MNKD has been reduced compared to a year ago.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -6.62, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MNKD (-6.62) is worse than 67.50% of its industry peers.
The Debt to FCF ratio of MNKD is 16.66, which is on the high side as it means it would take MNKD, 16.66 years of fcf income to pay off all of its debts.
MNKD's Debt to FCF ratio of 16.66 is amongst the best of the industry. MNKD outperforms 92.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 16.66
Altman-Z -6.62
ROIC/WACC1.29
WACC8.95%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

MNKD has a Current Ratio of 4.54. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Current ratio (4.54) which is comparable to the rest of the industry.
MNKD has a Quick Ratio of 4.17. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Quick ratio of 4.17. This is comparable to the rest of the industry: MNKD outperforms 49.73% of its industry peers.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 4.17
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

8

3. Growth

3.1 Past

MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 141.67%, which is quite impressive.
The Revenue has grown by 51.30% in the past year. This is a very strong growth!
MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.13% yearly.
EPS 1Y (TTM)141.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)51.3%
Revenue growth 3Y45.12%
Revenue growth 5Y48.13%
Sales Q2Q%36.73%

3.2 Future

MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.58% yearly.
Based on estimates for the next years, MNKD will show a very strong growth in Revenue. The Revenue will grow by 20.76% on average per year.
EPS Next Y320.32%
EPS Next 2Y164.54%
EPS Next 3Y105.66%
EPS Next 5Y70.58%
Revenue Next Year45.04%
Revenue Next 2Y31.29%
Revenue Next 3Y25.41%
Revenue Next 5Y20.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 115.20, MNKD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MNKD is valued cheaper than 92.72% of the companies in the same industry.
MNKD is valuated expensively when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 23.05 indicates a rather expensive valuation of MNKD.
93.78% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.70. MNKD is around the same levels.
Industry RankSector Rank
PE 115.2
Fwd PE 23.05
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 95.03% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 93.43% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 55.02
EV/EBITDA 25.57
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 105.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y164.54%
EPS Next 3Y105.66%

More info and screens

0

5. Dividend

5.1 Amount

MNKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANNKIND CORP

NASDAQ:MNKD (2/21/2025, 8:00:01 PM)

After market: 5.8001 +0.04 (+0.7%)

5.76

+0.1 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners61.62%
Inst Owner Change-92.18%
Ins Owners1.42%
Ins Owner Change-1.14%
Market Cap1.59B
Analysts85.45
Price Target10.2 (77.08%)
Short Float %10.08%
Short Ratio11.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.81%
Min EPS beat(2)-246.98%
Max EPS beat(2)-34.64%
EPS beat(4)1
Avg EPS beat(4)-82.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)50.83%
EPS beat(8)4
Avg EPS beat(8)-13.97%
EPS beat(12)5
Avg EPS beat(12)-13.1%
EPS beat(16)6
Avg EPS beat(16)-11.74%
Revenue beat(2)1
Avg Revenue beat(2)0.86%
Min Revenue beat(2)-7.78%
Max Revenue beat(2)9.49%
Revenue beat(4)3
Avg Revenue beat(4)4.03%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)5
Avg Revenue beat(8)4.04%
Revenue beat(12)8
Avg Revenue beat(12)5.01%
Revenue beat(16)12
Avg Revenue beat(16)7.55%
PT rev (1m)6.19%
PT rev (3m)28.21%
EPS NQ rev (1m)20%
EPS NQ rev (3m)20%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)0.16%
Revenue NQ rev (3m)-1.03%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-1.76%
Valuation
Industry RankSector Rank
PE 115.2
Fwd PE 23.05
P/S 5.94
P/FCF 55.02
P/OCF 38.24
P/B N/A
P/tB N/A
EV/EBITDA 25.57
EPS(TTM)0.05
EY0.87%
EPS(NY)0.25
Fwd EY4.34%
FCF(TTM)0.1
FCFY1.82%
OCF(TTM)0.15
OCFY2.62%
SpS0.97
BVpS-0.76
TBVpS-0.79
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.65%
ROE N/A
ROCE 14.6%
ROIC 11.54%
ROICexc 32.19%
ROICexgc 33.94%
OM 21.43%
PM (TTM) 8.07%
GM 71.91%
FCFM 10.81%
ROA(3y)-19.1%
ROA(5y)-33.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.96%
GM growth 5Y21.68%
F-Score9
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 16.66
Debt/EBITDA 7.21
Cap/Depr 196.83%
Cap/Sales 4.74%
Interest Coverage 2.39
Cash Conversion 65.23%
Profit Quality 133.88%
Current Ratio 4.54
Quick Ratio 4.17
Altman-Z -6.62
F-Score9
WACC8.95%
ROIC/WACC1.29
Cap/Depr(3y)443.89%
Cap/Depr(5y)363.79%
Cap/Sales(3y)14.72%
Cap/Sales(5y)11.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)141.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y320.32%
EPS Next 2Y164.54%
EPS Next 3Y105.66%
EPS Next 5Y70.58%
Revenue 1Y (TTM)51.3%
Revenue growth 3Y45.12%
Revenue growth 5Y48.13%
Sales Q2Q%36.73%
Revenue Next Year45.04%
Revenue Next 2Y31.29%
Revenue Next 3Y25.41%
Revenue Next 5Y20.76%
EBIT growth 1Y715.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y129.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y145.83%
OCF growth 3YN/A
OCF growth 5YN/A